These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35354187)

  • 1. Do Cannabis and Cannabinoids Have a Psychopharmacotherapeutic Effect?
    Pajević I; Hasanović M; Žigić N; Pajević A; Avdić L
    Psychiatr Danub; 2021; 33(Suppl 4):1196-1203. PubMed ID: 35354187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.
    Chesney E; Oliver D; McGuire P
    Psychopharmacology (Berl); 2022 May; 239(5):1179-1190. PubMed ID: 34255100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis, cannabinoids, and health.
    Lafaye G; Karila L; Blecha L; Benyamina A
    Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry.
    Hill KP; Gold MS; Nemeroff CB; McDonald W; Grzenda A; Widge AS; Rodriguez C; Kraguljac NV; Krystal JH; Carpenter LL
    Am J Psychiatry; 2022 Feb; 179(2):98-109. PubMed ID: 34875873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.
    Martinez Naya N; Kelly J; Corna G; Golino M; Polizio AH; Abbate A; Toldo S; Mezzaroma E
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38257386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies.
    Varshney K; Patel A; Ansari S; Shet P; Panag SS
    Cannabis Cannabinoid Res; 2023 Oct; 8(5):716-730. PubMed ID: 37253174
    [No Abstract]   [Full Text] [Related]  

  • 8. The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.
    Chye Y; Christensen E; Solowij N; Yücel M
    Front Psychiatry; 2019; 10():63. PubMed ID: 30837904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of Δ
    Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
    Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids in clinical practice.
    Williamson EM; Evans FJ
    Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool.
    Kapler S; Adery L; Hoftman GD; Amir CM; Grigoryan V; Cooper ZD; Bearden CE
    Psychol Med; 2024 Jan; 54(2):245-255. PubMed ID: 37882050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents.
    Hotham J; Cannings-John R; Moore L; Hawkins J; Bonell C; Hickman M; Zammit S; Hines LA; Adara L; Townson J; White J
    Br J Psychiatry; 2023 Oct; 223(4):478-484. PubMed ID: 37485911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Synthetic cannabis': A dangerous misnomer.
    Darke S; Banister S; Farrell M; Duflou J; Lappin J
    Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….
    Baron EP
    Headache; 2015 Jun; 55(6):885-916. PubMed ID: 26015168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing the science on cannabis concentrates and behavioural health.
    Bidwell LC; Martin-Willett R; Karoly HC
    Drug Alcohol Rev; 2021 Sep; 40(6):900-913. PubMed ID: 33783029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge and Opinion on Cannabinoids Among Orthopaedic Traumatologists.
    Chin G; Etiz BAF; Nelson AM; Lim PK; Scolaro JA
    J Am Acad Orthop Surg Glob Res Rev; 2021 Apr; 5(4):. PubMed ID: 33872227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.